基于限定日剂量和帕累托分析法对复方氨林巴比妥注射液和洛芬待因缓释片的药物利用评价  

Drug utilization of compound aminophenazone and barbital injection and compound codeine phosphate and ibuprofen sustained release tablets based on DDD and pareto analysis method

作　　者：程静茹 郝卓璐 陈新羽 焦灵利[2] 李明[2] 马丹华[2] 于丹丹[2] 唐少文[1] CHENG Jingru;HAO Zhuolu;CHEN Xinyu;JIAO Lingli;LI Ming;MA Danhua;YU Dandan;TANG Shaowen(不详;School of Public Health Nanjing Medical University,Nanjing 211166,China)

机构地区：[1]南京医科大学公共卫生学院,南京市211166 [2]江苏省药品不良反应监测中心,南京市210002

出　　处：《临床合理用药杂志》2024年第12期37-40,44,共5页Chinese Journal of Clinical Rational Drug Use

基　　金：江苏省药品监督管理局科研计划课题(202008)。

摘　　要：目的基于限定日剂量和帕累托分析法分析医疗机构复方氨林巴比妥注射液(以下简称为复方氨林巴比妥)与洛芬待因缓释片药物利用情况,为医疗机构药品管理及药物滥用主动监测提供参考。方法收集南京医科大学大数据平台(来自4家医院2016年9月—2022年8月电子病历)中复方氨林巴比妥或洛芬待因缓释片的处方信息,最终获得处方中开具复方氨林巴比妥的患者4261例(病历4552份),处方中开具洛芬待因缓释片的患者3278例(病历3817份)。根据限定日剂量评价用药倾向和用药合理性,使用帕累托分析法评价药品使用合理性。采用Spearman秩相关分析探讨年龄与复方氨林巴比妥单次剂量、实际日剂量的关系。结果处方复方氨林巴比妥注射液的患者男女比例为1.14∶1,诊断主要为呼吸道感染,主要就诊科室为急诊科;处方洛芬待因缓释片的患者男女比例为1.05∶1,主要就诊科室为疼痛科。复方氨林巴比妥2019年用药频度(DDDs)最高,洛芬待因缓释片2020年DDDs最高。2019年复方氨林巴比妥的消耗量和实际用药天数最多,同年DDDs也最高,各年药物利用指数(DUI)均<1。Spearman秩相关分析结果显示,年龄与复方氨林巴比妥单次剂量(r_(s)=0.07,P<0.05)和实际日剂量(r_(s)=0.06,P<0.05)均呈弱相关。2020年洛芬待因缓释片的消耗总量和实际用药天数最多,同年DDDs最多,各年DUI均<1。处方开具复方氨林巴比妥、洛芬待因缓释片的患者中开药次数1次为A因素。复方氨林巴比妥开药次数3~7次为C类因素。洛芬待因缓释片开药次数4~11次为C类因素。结论2种药品总体用药情况均符合药品说明书要求,但存在个体用药不合理现象,医疗机构应加强管理,重点关注开药次数较多患者,防止药物过度使用甚至滥用。Objective This study aims to analyze the utilization of compound aminophenazone and barbital injection and compound codeine phosphate and ibuprofen sustained release tablets in medical institutions based on DDD and pareto analysis method,providing references for drug management and proactive monitoring of drug abuse.Methods Prescription information regarding compound aminophenazone and barbital injection or compound codeine phosphate and ibuprofen sustained release tablets were collected from the big data platform of Nanjing Medical University(from September 2016 to August 2022,electronic medical records from 4 hospitals).The study finally obtained 4261 cases(4552 medical records)of patients prescribed compound aminophenazone and barbital injection and 3278 cases(3817 medical records)of patients prescribed compound codeine phosphate and ibuprofen sustained release tablets.The rationality of drug use was evaluated based on the defined daily dose and pareto analysis method.Spearman rank correlation analysis was used to analysis the relationship of age with single dose and actual daily dose of compound aminophenazone and barbital.Results The male-to-female ratio of patients prescribed compound aminophenazone and barbital injection was 1.14∶1,and the main diagnosis was respiratory tract infection,with the main department being the Emergency Department.The male-to-female ratio of patients prescribed compound codeine phosphate and ibuprofen sustained release tablets was 1.05∶1,with the main department being the Pain Department.The highest DDDs for compound aminophenazone and barbital injection occurred in 2019,while the highest DDDs for compound codeine phosphate and ibuprofen sustained release tablets occurred in 2020.In 2019,compound aminophenazone and barbital injection had the highest consumption and actual days of medication,with all the annual DUI being less than 1.Spearman rank correlation analysis showed that,age was weakly correlated with single dose(r_(s)=0.07,P<0.05)and actual daily dose of compound amin

关 键 词：药物利用评价 限定日剂量 帕累托分析 复方氨林巴比妥注射液 洛芬待因缓释片 大数据平台 

分 类 号：R969[医药卫生—药理学]